Related Experiment Video
Updated: Apr 14, 2026
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
Published on: August 22, 2016
Pharmacokinetics and osteogenic potential of PEGylated NELL-1 in vivo after systemic administration
Jin Hee Kwak1, Yulong Zhang2, Juyoung Park3
1Division of Growth and Development and Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Craniofacial Research Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Abstract:
Osteoporosis is a skeletal disorder attributable to an imbalance in osteoblast and osteoclast activity. NELL-1, a secretory protein that promotes osteogenesis while suppressing osteoclastic activity, holds potential as an osteoporosis therapy. Recently, we demonstrated that PEGylation of NELL-1 significantly improves its thermostability while preserving its bioactivity in vitro. However, the effect of PEGylation on the pharmacokinetics and osteogenic potential of NELL-1 in vivo have yet to be investigated. The present study demonstrated that PEGylation of NELL-1 significantly increases the elimination half-life time of the protein from 5.5 h to 15.5 h while distributing more than 2-3 times the amount of protein to bone tissues (femur, tibia, vertebrae, calvaria) in vivo when compared to naked NELL-1. In addition, microCT and DXA analyses demonstrated that systemic NELL-PEG therapy administered every 4 or 7 days significantly increases not only femoral and lumbar BMD and percent bone volume, but also new bone formation throughout the overall skeleton after four weeks of treatment. Furthermore, immunohistochemistry revealed increased osteocalcin expression, while TRAP staining showed reduced osteoclast numbers in NELL-PEG groups. Our findings suggest that the PEGylation technique presents a viable and promising approach to further develop NELL-1 into an effective systemic therapeutic for the treatment of osteoporosis.
Insights
PEGylation of NELL-1 enhances its bone targeting and therapeutic potential for osteoporosis. This modified protein shows improved pharmacokinetics and promotes significant bone formation in vivo.
Area of Science:
- Biochemistry
- Orthopedics
- Pharmacology
Background:
- Osteoporosis is a bone disorder caused by imbalanced osteoblast and osteoclast activity.
- NELL-1 protein shows promise for osteoporosis treatment by promoting bone formation and inhibiting bone resorption.
- PEGylation of NELL-1 improves its stability and bioactivity in vitro.
Purpose of the Study:
- To investigate the in vivo pharmacokinetics and osteogenic potential of PEGylated NELL-1 (NELL-PEG).
- To evaluate the efficacy of NELL-PEG as a systemic therapy for osteoporosis.
Main Methods:
- PEGylation of NELL-1 protein.
- In vivo pharmacokinetic studies measuring elimination half-life and bone distribution.
- MicroCT and DXA analyses for bone mineral density and bone volume assessment.
- Immunohistochemistry for osteocalcin expression and TRAP staining for osteoclast activity.
Main Results:
- PEGylation significantly increased NELL-1's elimination half-life from 5.5 h to 15.5 h.
- NELL-PEG showed 2-3 times greater distribution to bone tissues (femur, tibia, vertebrae, calvaria) compared to native NELL-1.
- Systemic NELL-PEG therapy increased bone mineral density, bone volume, and new bone formation in vivo.
- Increased osteocalcin expression and reduced osteoclast numbers were observed in NELL-PEG treated groups.
Conclusions:
- PEGylation is a viable strategy to enhance the pharmacokinetic properties and bone-targeting capabilities of NELL-1.
- NELL-PEG demonstrates significant therapeutic potential as a systemic treatment for osteoporosis.
- Further development of NELL-PEG could lead to an effective therapy for osteoporosis.
More Related Videos
10:32Author Spotlight: Simple Establishment of a Vascularized Osteogenic Bone Marrow Niche Using Pre-Cast Poly(Ethylene Glycol) (PEG) Hydrogels in an Imaging Microplate
Published on: May 19, 2023
07:53Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
